Videos
A Case of HR+ Metastatic Breast Cancer
JAK Inhibition for the Management of Primary Myelofibrosis
Primary Myelofibrosis
CLL Case Review: IgHV-Unmutated Therapy Options
David S. Hong, MD, discusses the potential for other TRK inhibitors in the treatment landscape for patients with thyroid cancer after the approval of larotrectinib.
Andre Goy, MD, discusses a few combinations that are being investigated for the treatment of patients with relapsed/refractory mantle cell lymphoma.
High-Risk IgVH-Unmutated Chronic Lymphocytic Leukemia
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Generic Larotrectinib Capsules Gain Tentative FDA Approval
2
Tarlatamab Shows Activity in SCLC With Brain Metastases in Real-World Cohort
3
FDA Grants Rare Pediatric Disease Designation to Opaganib for Neuroblastoma
4
ASCO 2026 Highlights: Breast & Lung Cancer Advances With Ajaz Khan, MD
5